Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898349 | 0.89 | NPC1 (0.44) | MAPTRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4869815 | 0.88 | MAPT (0.43) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL2172191 | 0.77 | NPC1 (0.50) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2172195 | 0.77 | NPC1 (0.50) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4554972 | 0.73 | MAPT (0.69) | MAPTRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4862251 | 0.72 | TP53 (0.67) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL4870689 | 0.72 | NPC1 (0.50) | MAPTRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4863835 | 0.72 | MAPT (0.47) | MAPTRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4863830 | 0.72 | TP53 (0.66) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL4869862 | 0.71 | MAPT (0.54) | MAPTRAB9ANPC1SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | MAPT 3398/4885RAB9A 4025/4885ALDH1A1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.